- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 210
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Select Advanced Solid Tumors
- Interventions
- IMC-C103C, Atezolizumab
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986288, Nivolumab, Regorafenib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 6
- States / cities
- Costa Mesa, California • Orange, California • Aurora, Colorado + 3 more
- Conditions
- Tumor, Solid
- Interventions
- Durvalumab and Tremelimumab
- Drug
- Lead sponsor
- John L. Villano, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 6
- States / cities
- Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
- Conditions
- Gynecologic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- FT536, Fludarabine, CY
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Solid Tumor, Adult
- Interventions
- DF9001, KEYTRUDA® (pembrolizumab)
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
- Conditions
- Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- Domvanalimab, Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986299, Nivolumab, Ipilimumab
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- La Jolla, California • Orange, California • Sacramento, California + 6 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 55
- States / cities
- Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
- Interventions
- ONM-501, Cemiplimab
- Drug
- Lead sponsor
- OncoNano Medicine, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
- Interventions
- FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Interventions
- SLC-391, pembrolizumab
- Drug · Biological
- Lead sponsor
- SignalChem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
- Conditions
- Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
- Interventions
- EWSR1 immunotherapy, Pembrolizumab
- Drug
- Lead sponsor
- Rabi Hanna
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostate Cancer
- Interventions
- STM-416p
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Gainesville, Florida
- Conditions
- Breast Cancer
- Interventions
- NeuVax vaccine, Trastuzumab, GM-CSF
- Biological · Drug
- Lead sponsor
- Cancer Insight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 24
- States / cities
- Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 8
- States / cities
- Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Interventions
- INCA00186, Retifanlimab, INCB106385
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more
- Conditions
- Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
- Interventions
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
- Combination Product · Drug
- Lead sponsor
- PDS Biotechnology Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
- Interventions
- ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
- Biological · Drug · Procedure
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer
- Interventions
- RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Biological · Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Cobimetinib, Vemurafenib
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
- Interventions
- PF-07265028, Sasanlimab
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more